Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis
In this large nationwide study, rituximab and IL-6i users had numerically higher, but not statistically significant, MACE risk. Our data support the safety of b/tsDMARD use for RA treatment. This study was limited by short follow-up time and confounding by indication; further studies that can overcome these limitations are needed.
Authors
- Namrata Singh (ORCID: https://orcid.org/0000-0001-7149-363X)
- Jeffrey A. Sparks (ORCID: https://orcid.org/0000-0002-5556-4618)
- James S. Andrews (ORCID: https://orcid.org/0000-0003-2302-4358)
- Radjiv Goulabchand (ORCID: https://orcid.org/0000-0002-7328-4097)
- Laura S. Gold (ORCID: https://orcid.org/0000-0002-4289-5231)
- Maureen Dubreuil (ORCID: https://orcid.org/0000-0002-6253-1515)
- David Liew (ORCID: https://orcid.org/0000-0001-8451-8883)
- Jeffrey G. Jarvik (ORCID: https://orcid.org/0000-0002-0528-3455)
- Pankti Reid (ORCID: https://orcid.org/0000-0002-7645-0919)
- Jean W. Liew (ORCID: https://orcid.org/0000-0002-8104-2450)
- Xavier Sendaydiego
- Grant C. Hughes (ORCID: https://orcid.org/0000-0003-1856-2493)
- Siddharth Singh
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Inserm (FR)
- University of San Diego (US)
- The University of Melbourne (AU)
- Université de Montpellier (FR)
- University of Washington (US)
- VA Boston Healthcare System (US)
- University of Alabama at Birmingham (US)
- University of California San Diego (US)
- University of Chicago Medical Center (US)
- Geriatric Research Education and Clinical Center (US)
- Washington Center (US)
- Austin Health (AU)
- Université de Nîmes (FR)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1093/rheumatology/keaf096
- Citations
- 7
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 11.68